KCNK7
ENSG00000173338
Chromosome
11
- Chemical probe available
- No
- Other names
- K2p7.1
- Target name
- KCNK7
- Gene name
- Potassium two pore domain channel subfamily K member 7
- Gene symbol
- KCNK7
- Protein name
- Potassium channel subfamily K member 7
- Gene biotype
- Protein coding
- Gene family
- Potassium two pore domain channel subfamily K
- Target type
- Human gene
- Tissues expressed in
- 36
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 83.66
- Tissue specificity (Gini)
- 0.746
- Tissue specificity (tau)
- 0.96
- KEGG gene identifiers
- hsa:10089
- Protein interaction confidence
- 0.80725
- Protein interaction partners
- 4
- R-HSA-1299308
- R-HSA-5576886
- End position
- 65595996
- Start position
- 65592836
- Chromosome
- 11
- Strand
- Reverse
- Membrane
- Multi-pass membrane protein .
- Plasma membrane
- Tissue specificity (tau)
- 0.959632
- Expression inequality (Gini)
- 0.746227
Expression in transcripts per million
- Skin - Not Sun Exposed (Suprapubic)
- 83.66
- Skin - Sun Exposed (Lower leg)
- 79.96
- Esophagus - Mucosa
- 12.87
- Vagina
- 7.42
- Brain - Cerebellar Hemisphere
- 5.01
Expression in transcripts per million
- Skin - Not Sun Exposed (Suprapubic)83.66
- Skin - Sun Exposed (Lower leg)79.96
- Esophagus - Mucosa12.87
- Vagina7.42
- Brain - Cerebellar Hemisphere5.01
- Brain - Cerebellum4.9
- Nerve - Tibial3.62
- Whole Blood3.33
- Fallopian Tube2.71
- Bladder2.54
- Cervix - Ectocervix2.46
- Spleen2.4
- Colon - Sigmoid2.37
- Uterus2.36
- Esophagus - Gastroesophageal Junction2.18
- Lung2.06
- Cervix - Endocervix1.99
- Esophagus - Muscularis1.99
- Artery - Coronary1.96
- Ovary1.92
- Brain - Frontal Cortex (BA9)1.91
- Brain - Cortex1.9
- Artery - Tibial1.89
- Artery - Aorta1.82
- Brain - Spinal cord (cervical c-1)1.74
And 29 more, listed on the interactive page.
Biological processes
- GO:0006813
Cellular components
- GO:0005886
Molecular functions
- GO:0005267
Related records
Trials (559)
- "Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes"
- "Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial"
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
- A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
- A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients
- A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin
- A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.
- A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)
- A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes
- A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
- A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
- A Phase 2b Diabetic Kidney Disease Study
- A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
- A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants
- A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment
- A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects
- A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
- A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure